Key result
New warfarin users show suboptimal anticoagulation control, with ~82% failing to achieve optimal TTR.
Why the study?
Time in therapeutic range (TTR) of ≥70% indicates optimal anticoagulation control, but patterns and predictors of control in new warfarin users required determination.
What patient-related factors are associated with optimal anticoagulation control (TTR ≥70%) in new users of warfarin?
Cohort (n=6,032)
What patient-related factors are associated with optimal anticoagulation control (TTR ≥70%) in new users of warfarin?
In a New Zealand cohort of new warfarin users, anticoagulation control was generally suboptimal, with younger age, minority ethnicity, and socioeconomic deprivation predicting poorer time in therapeutic range.
Younger age, minority ethnicity, and deprivation predict poorer TTR on warfarin; leaves open whether targeted strategies improve control.
OBJECTIVES: Time in therapeutic range (TTR) of ≥70% is a commonly used indicator of optimal anticoagulation control. This study aimed to determine the patterns and predictors of anticoagulation control in a population-based cohort of new users of warfarin. METHODS: This was a retrospective cohort study. All adults (age ≥18 years) who had been newly initiated on warfarin therapy between January 2006 and March 2011were selected from administrative health databases. TTR was calculated using the Rosendaal method. Multivariable logistic regression models were used to identify patient-related factors associated with optimal TTR. Predictors of patients spending >30% of time above and below the therapeutic international normalised ratio (INR) range were also examined. KEY FINDINGS: A total of 6032 patients were included in this study. The mean TTR was 54.1 ± 18.8%, and 82.3% of patients had subthreshold TTR (<70%). Compared with New Zealand Europeans, Māori and Pacific people had decreased odds of achieving optimal TTR and increased odds of spending >30% of time below the therapeutic INR range. Patients aged 65-74 years and 75 years or older had increased odds of achieving optimal TTR but decreased odds of spending >30% of time below the therapeutic INR range than those <65 years. Compared with those living in the least socioeconomically deprived areas, those living in the most deprived areas had decreased odds of achieving optimal TTR. CONCLUSIONS: Anticoagulation control with warfarin is suboptimal in routine care in New Zealand. Age, ethnicity and deprivation index were significant predictors of TTR. It is important to ensure equitable access to appropriate, high-quality care for those living in deprived areas and those from ethnic minority groups.
No takes yet. Share an insight, caveat, or question.
Beyene et al. (2021) conducted a cohort in Anticoagulation therapy (n=6,032). Warfarin was evaluated on Optimal time in therapeutic range (TTR) ≥70%. Among 6032 new users of warfarin, anticoagulation control was suboptimal with a mean TTR of 54.1%, and 82.3% of patients failing to achieve the optimal TTR threshold of ≥70%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: